Chat with MASH AI
Hi, I am MASH AI.
Suggested Questions :
MASH AI 06:09 PM
At January 23, 2025
Thank you to Madrigal for sponsoring the Medication Review Video Module.
In this GHAPP Medication Review video, Robin Soto, a board-certified nurse practitioner at UC San Diego Health Hepatology, explains the mechanism of action of Resmetirom, the first and only FDA-approved drug for the treatment of MASH in adults with mild to moderate fibrosis (F2-F3). Robin describes how Resmetirom, a liver-directed, thyroid hormone receptor beta agonist, targets liver fat accumulation, promoting fatty acid oxidation and improving cholesterol metabolism. She highlights its anti-inflammatory effects and ability to reduce liver fibrosis by selectively activating receptors in the liver, while minimizing systemic side effects. For more information, visit the GHAPP website and ACE app.
Related Medication Review
What is the clinical profile of Resmetirom, including dosing schedules?
At Jan 23, 2025
Thank you to Madrigal for sponsoring this Medication Review Video Module! In this GHAPP Medication Review Video Module, nurse practitioner Whitney Steinmetz discusses the clinical profile of Resmetirom, a thyroid hormone receptor beta agonist indicated for adults with metabolic-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. Whitney explores the mechanism of action, dosage recommendations, and the dual primary endpoint success of Resmetirom in clinical trials. She highlights key considerations, including drug interactions and common side effects such as nausea and diarrhea, and how they are generally well-tolerated over time. Learn more about Resmetirom's impact on liver health and patient care by visiting the GHAPP website or app.
Watch Now